Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers

Abstract Early diagnosis of cancer and early detection of relapse following surgery are critical for the effective treatment of the disease and for a positive clinical outcome. Identification of novel diagnostic, prognostic and predictive biomarkers will contribute utmost to clinical decision-making. The human tissue kallikrein and kallikrein-related peptidases (KLKs), encoded by the largest contiguous cluster of protease genes in the human genome, are secreted serine proteases with diverse expression patterns and physiological roles. The aberrant expression of KLKs in various malignancies as well as their involvement in many cancer-related processes, such as cell growth regulation, angiogenesis, invasion, and metastasis, has prompted scientists to investigate their potential as cancer biomarkers. Expression of distinct KLKs is associated with clinicopathological parameters of cancer patients. Moreover, several KLKs possess significant favorable or unfavorable prognostic value in various malignancies, with prostate-specific antigen (PSA) being the most widely used biomarker in clinical practice, today. KLKs are also considered as very promising biomarkers for cancer personalized medicine, especially for prediction and monitoring of patients’ response to chemotherapy, therefore opening up new horizons towards effective patient monitoring post-treatment. This review describes the current status of KLKs as tumor biomarkers.

[1]  HORMONAL REGULATION , 1938, British medical journal.

[2]  P. Riegman,et al.  Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. , 1989, Biochemical and biophysical research communications.

[3]  P. Riegman,et al.  The prostate‐specific antigen gene and the human glandular kallikrein‐1 gene are tandemly located on chromosome 19 , 1989, FEBS letters.

[4]  S. Taylor.  Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.

[5]  D. Tindall,et al.  Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. , 1992, Biochemistry.

[6]  D. Tindall,et al.  Hormonal regulation of prostate‐specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP , 1992, The Prostate.

[7]  E. Diamandis,et al.  Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. , 1994, Clinical biochemistry.

[8]  P. Wallbrandt,et al.  Cloning, expression, and characterization of stratum corneum chymotryptic enzyme. A skin-specific human serine proteinase. , 1994, The Journal of biological chemistry.

[9]  A. Passaniti,et al.  Regulation of prostate‐specific antigen gene expression in LNCaP human prostatic carcinoma cells by growth, dihydrotestosterone, and extracellular matrix , 1994, The Prostate.

[10]  D. Tindall,et al.  Expression and androgenic regulation of human prostate-specific kallikreins. , 1995, Journal of andrology.

[11]  D. Wazer,et al.  Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. , 1996, Cancer research.

[12]  S. Mok,et al.  A Novel Protease Homolog Differentially Expressed in Breast and Ovarian Cancer , 1996, Molecular medicine.

[13]  James R. Miller,et al.  Zyme, a Novel and Potentially Amyloidogenic Enzyme cDNA Isolated from Alzheimer’s Disease Brain* , 1997, The Journal of Biological Chemistry.

[14]  T. Tanaka,et al.  Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain. , 1997, Biochimica et biophysica acta.

[15]  E. Diamandis,et al.  Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. , 1997, British Journal of Cancer.

[16]  S. Yoshida,et al.  cDNA cloning and expression of a novel serine protease, TLSP. , 1998, Biochimica et biophysica acta.

[17]  S. Yoshida,et al.  Sequence analysis and expression of human neuropsin cDNA and gene. , 1998, Gene.

[18]  G. Yousef,et al.  Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. , 1999, Anticancer research.

[19]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[20]  E. Diamandis,et al.  Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. , 1999, Clinical chemistry.

[21]  K. Shigemasa,et al.  Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. , 1999, Cancer research.

[22]  M. Brattsand,et al.  Purification, Molecular Cloning, and Expression of a Human Stratum Corneum Trypsin-like Serine Protease with Possible Function in Desquamation* , 1999, The Journal of Biological Chemistry.

[23]  W. Catalona,et al.  The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. , 1999, Clinical chemistry.

[24]  M. Hentze,et al.  A Perfect Message RNA Surveillance and Nonsense-Mediated Decay , 1999, Cell.

[25]  G. Yousef,et al.  Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. , 2000, Biochemical and biophysical research communications.

[26]  P. Nelson,et al.  New nomenclature for the human tissue kallikrein gene family. , 2000, Clinical chemistry.

[27]  J. Clements,et al.  Tissue-specific Expression Patterns and Fine Mapping of the Human Kallikrein (KLK) Locus on Proximal 19q13.4* , 2000, The Journal of Biological Chemistry.

[28]  N. Yamaguchi,et al.  A novel isoform of a kallikrein-like protease, TLSP/hippostasin, (PRSS20), is expressed in the human brain and prostate. , 2000, Biochemical and biophysical research communications.

[29]  P. Kantoff,et al.  A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  G. Yousef,et al.  The expanded human kallikrein gene family: locus characterization and molecular cloning of a new member, KLK-L3 (KLK9). , 2000, Genomics.

[31]  G. Yousef,et al.  Genomic organization, mapping, tissue expression, and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kallikrein gene family. , 2000, Genomics.

[32]  Eleftherios P. Diamandis,et al.  The New Human Kallikrein Gene Family: Implications in Carcinogenesis , 2000, Trends in Endocrinology & Metabolism.

[33]  S. Naber,et al.  Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  G. Yousef,et al.  The new human tissue kallikrein gene family: structure, function, and association to disease. , 2001, Endocrine reviews.

[35]  D. Botstein,et al.  Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Basuyau,et al.  Determination of Tumor Markers in Serum. Pitfalls and Good Practice , 2001, Clinical chemistry and laboratory medicine.

[37]  F. L. Tello,et al.  Free and Complexed Prostate-Specific Antigen (PSA) in the Early Detection of Prostate Cancer , 2001, Clinical chemistry and laboratory medicine.

[38]  S. Sukumar,et al.  CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. , 2001, Cancer research.

[39]  D. Chan,et al.  Concentration of enzymatically active prostate‐specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models , 2001, The Prostate.

[40]  P. Sismondi,et al.  Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. , 2002, Clinical chemistry.

[41]  G. Caliendo,et al.  Design of Inhibitors for Human Tissue Kallikrein Using Non-Natural Aromatic and Basic Amino Acids , 2002, Biological chemistry.

[42]  J. Foekens,et al.  Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance , 2002, British Journal of Cancer.

[43]  P. Sismondi,et al.  Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis , 2002, British Journal of Cancer.

[44]  Hartwig Huland,et al.  Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. , 2003, The Journal of urology.

[45]  J. Clements,et al.  Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  G. Yousef,et al.  Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. , 2003, Cancer research.

[47]  George M Yousef,et al.  Genomic overview of serine proteases. , 2003, Biochemical and biophysical research communications.

[48]  G. Yousef,et al.  An overview of the kallikrein gene families in humans and other species: emerging candidate tumour markers. , 2003, Clinical biochemistry.

[49]  A. Scorilas,et al.  Serum human glandular kallikrein (hK2) and insulin‐like growth factor 1 (IGF‐1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA , 2003, The Prostate.

[50]  G. Yousef,et al.  Human tissue kallikreins and testicular cancer , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[51]  M. Serio,et al.  Real-Time RT-PCR for the Measurement of Prostate-Specific Antigen mRNA Expression in Benign Hyperplasia and Adenocarcinoma of Prostate , 2003, Clinical chemistry and laboratory medicine.

[52]  G. Yousef,et al.  Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay. , 2003, Clinical chemistry.

[53]  K. Shigemasa,et al.  Expression of human kallikrein 7 (hK7/SCCE) and its inhibitor antileukoprotease (ALP/SLPI) in uterine endocervical glands and in cervical adenocarcinomas. , 2004, Oncology reports.

[54]  Kim Pettersson,et al.  Development of sensitive immunoassays for free and total human glandular kallikrein 2. , 2004, Clinical chemistry.

[55]  F. Prósper,et al.  Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. , 2004, Blood.

[56]  T. O'brien,et al.  The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in squamous cervical cancer cells. , 2004, Gynecologic oncology.

[57]  T. O'brien,et al.  The novel serine protease tumor-associated differentially expressed gene-14 (KLK8/Neuropsin/Ovasin) is highly overexpressed in cervical cancer. , 2004, American journal of obstetrics and gynecology.

[58]  E. Andreu,et al.  The normal epithelial cell-specific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3–4, is downregulated by hypermethylation in acute lymphoblastic leukemia , 2004, Leukemia.

[59]  E. Diamandis,et al.  The emerging roles of human tissue kallikreins in cancer , 2004, Nature Reviews Cancer.

[60]  E. Diamandis,et al.  Human tissue kallikreins: physiologic roles and applications in cancer. , 2004, Molecular cancer research : MCR.

[61]  G. Yousef,et al.  Cloning of a kallikrein pseudogene. , 2004, Clinical biochemistry.

[62]  J. Clements,et al.  The Tissue Kallikrein Family of Serine Proteases: Functional Roles in Human Disease and Potential as Clinical Biomarkers , 2004, Critical reviews in clinical laboratory sciences.

[63]  E. Diamandis,et al.  Association of kallikrein expression in nipple aspirate fluid with breast cancer risk , 2004, International journal of cancer.

[64]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[65]  B. Davidson,et al.  Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. , 2004, Gynecologic oncology.

[66]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[67]  E. Lemarié,et al.  KLK5 and KLK7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer. , 2005, Biochemical and biophysical research communications.

[68]  G. Yousef,et al.  Prognostic Implications of the Immunohistochemical Expression of Human Kallikreins 5, 6, 10 and 11 in Renal Cell Carcinoma , 2005, Tumor Biology.

[69]  E. Diamandis,et al.  Human tissue kallikrein gene family: applications in cancer. , 2005, Cancer letters.

[70]  A. Scorilas,et al.  Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[71]  D. Katsaros,et al.  Downregulation of Human Kallikrein 10 (KLK10/NES1) by CpG Island Hypermethylation in Breast, Ovarian and Prostate Cancers , 2005, Tumor Biology.

[72]  T. Utsunomiya,et al.  Clinicopathologic and Biological Significance of Kallikrein 6 Overexpression in Human Gastric Cancer , 2005, Clinical Cancer Research.

[73]  M. Brattsand,et al.  A proteolytic cascade of kallikreins in the stratum corneum. , 2005, The Journal of investigative dermatology.

[74]  G. Yousef,et al.  A survey of alternative transcripts of human tissue kallikrein genes. , 2005, Biochimica et biophysica acta.

[75]  Xabier Agirre,et al.  Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  E. Diamandis,et al.  Proteinase-activated Receptors, Targets for Kallikrein Signaling* , 2006, Journal of Biological Chemistry.

[77]  E. Diamandis,et al.  Purification and Characterization of Human Kallikrein 11, a Candidate Prostate and Ovarian Cancer Biomarker, from Seminal Plasma , 2006, Clinical Cancer Research.

[78]  E. Diamandis,et al.  The kallikrein world: an update on the human tissue kallikreins , 2006, Biological chemistry.

[79]  Y. Sher,et al.  Human kallikrein 8 protease confers a favorable clinical outcome in non-small cell lung cancer by suppressing tumor cell invasiveness. , 2006, Cancer research.

[80]  E. Diamandis,et al.  Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines , 2007, Breast Cancer Research and Treatment.

[81]  E. Diamandis,et al.  The epigenetic basis for the aberrant expression of kallikreins in human cancers , 2006, Biological chemistry.

[82]  A. Scorilas,et al.  mRNA expression analysis of human kallikrein 11 (KLK11) may be useful in the discrimination of benign prostatic hyperplasia from prostate cancer after needle prostate biopsy , 2006, Biological chemistry.

[83]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  D. Wazer,et al.  Human kallikrein 10, a predictive marker for breast cancer , 2006, Biological chemistry.

[85]  M. Yunokawa,et al.  Expression of Tumor-Associated Differentially Expressed Gene-14 (TADG-14/KLK8) and Its Protein hK8 in Uterine Endometria and Endometrial Carcinomas , 2006, Tumor Biology.

[86]  J. Clements,et al.  A comprehensive nomenclature for serine proteases with homology to tissue kallikreins , 2006, Biological chemistry.

[87]  M Dietel,et al.  Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status , 2006, British Journal of Cancer.

[88]  J. Schouten,et al.  Epigenetic events of disease progression in head and neck squamous cell carcinoma. , 2006, Archives of otolaryngology--head & neck surgery.

[89]  J. Clements,et al.  Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function? , 2006, Biological chemistry.

[90]  Klaus Jung,et al.  Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer , 2006, International journal of urology : official journal of the Japanese Urological Association.

[91]  E. Diamandis,et al.  A Potential Role for Multiple Tissue Kallikrein Serine Proteases in Epidermal Desquamation* , 2006, Journal of Biological Chemistry.

[92]  E. Diamandis,et al.  Distribution of 15 human kallikreins in tissues and biological fluids. , 2007, Clinical chemistry.

[93]  G. Sotiropoulou,et al.  Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. , 2007, Biochimica et biophysica acta.

[94]  Klaus Jung,et al.  PSA and other tissue kallikreins for prostate cancer detection. , 2007, European journal of cancer.

[95]  D. Katsaros,et al.  A Multiparametric Panel for Ovarian Cancer Diagnosis, Prognosis, and Response to Chemotherapy , 2007, Clinical Cancer Research.

[96]  Nicole Urban,et al.  CA125 in ovarian cancer. , 2007, Biomarkers in medicine.

[97]  C. P. Morris,et al.  PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. , 2006, Carcinogenesis.

[98]  Jennifer L. Harris,et al.  Defining the extended substrate specificity of kallikrein 1-related peptidases , 2007, Biological chemistry.

[99]  T. Gilligan.  Testis cancer: rare, but curable with prompt referral. , 2007, Cleveland Clinic journal of medicine.

[100]  Miltiadis Paliouras,et al.  Human tissue kallikreins: the cancer biomarker family. , 2007, Cancer letters.

[101]  Wei Huang,et al.  Downregulation and CpG island hypermethylation of NES1/hK10 gene in the pathogenesis of human gastric cancer. , 2007, Cancer letters.

[102]  E. Diamandis,et al.  Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung , 2008, Biological chemistry.

[103]  E. Diamandis,et al.  Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer , 2008, Molecular oncology.

[104]  E. Diamandis,et al.  A Multiparametric Serum Kallikrein Panel for Diagnosis of Non–Small Cell Lung Carcinoma , 2008, Clinical Cancer Research.

[105]  G. Yousef,et al.  Kallikreins as microRNA targets: an in silico and experimental-based analysis , 2008, Biological chemistry.

[106]  Georgia Sotiropoulou,et al.  Novel splice variants of prostate-specific antigen and applications in diagnosis of prostate cancer. , 2008, Clinical biochemistry.

[107]  A. Scorilas,et al.  Prognostic value of kallikrein‐related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA) , 2008, Cancer science.

[108]  E. Diamandis,et al.  Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel , 2008, British Journal of Cancer.

[109]  J. Clements.  Reflections on the tissue kallikrein and kallikrein-related peptidase family – from mice to men – what have we learnt in the last two decades? , 2008, Biological chemistry.

[110]  E. Diamandis,et al.  Substrate specificity determination of mouse implantation serine proteinase and human kallikrein-related peptidase 6 by phage display , 2008, Biological chemistry.

[111]  G. Emons,et al.  Hormonal heterogeneity of endometrial cancer. , 2008, Advances in experimental medicine and biology.

[112]  H. Samaratunga,et al.  Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs) , 2008, Biological chemistry.

[113]  G. Yousef.  microRNAs: a new frontier in kallikrein research , 2008, Biological chemistry.

[114]  E. Diamandis,et al.  Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. , 2008, Clinical chemistry.

[115]  A. Scorilas,et al.  Expression analysis and study of KLK4 in benign and malignant breast tumours , 2009, Thrombosis and Haemostasis.

[116]  E. Lianidou,et al.  Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[117]  L. Briollais,et al.  High kallikrein-related peptidase 6 in non-small cell lung cancer cells: an indicator of tumour proliferation and poor prognosis , 2009, Journal of cellular and molecular medicine.

[118]  A. Vlahou,et al.  A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition. , 2009, Cancer research.

[119]  E. Diamandis,et al.  Functional Roles of Human Kallikrein-related Peptidases* , 2009, The Journal of Biological Chemistry.

[120]  A. Scorilas,et al.  Quantitative Analysis of Human Kallikrein 5 (klk5) Expression in Prostate Needle Biopsies: an Independent Cancer Biomarker , 2022 .

[121]  Shellaine R. Frazier,et al.  Multiple kallikrein (KLK 5, 7, 8, and 10) expression in squamous cell carcinoma of the oral cavity. , 2009, Histology and histopathology.

[122]  A. Scorilas,et al.  Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11 , 2009, Thrombosis and Haemostasis.

[123]  G. Yousef,et al.  Human kallikrein related peptidases 6 and 13 in combination withCA125 is a more sensitive test for ovarian cancer than CA125 alone. , 2009, Cancer biomarkers : section A of Disease markers.

[124]  A. Scorilas,et al.  The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer , 2009, British Journal of Cancer.

[125]  A. Scorilas,et al.  Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer , 2009, Thrombosis and Haemostasis.

[126]  A. Scorilas,et al.  Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. , 2010, Future oncology.

[127]  V. Magdolen,et al.  Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs) , 2010, Biochimie.

[128]  George M Yousef,et al.  Personalized Medicine: Marking a New Epoch in Cancer Patient Management , 2010, Molecular Cancer Research.

[129]  A. Scorilas,et al.  Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia , 2010, Cancer science.

[130]  E. Ars,et al.  Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms. , 2010, The Journal of urology.

[131]  Athanasia Pavlopoulou,et al.  Evolutionary History of Tissue Kallikreins , 2010, PloS one.

[132]  Brian C Mackness,et al.  Polymer–protein-enhanced fluoroimmunoassay for prostate-specific antigen , 2010, Analytical and bioanalytical chemistry.

[133]  A. Scorilas,et al.  KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone , 2010, Biological chemistry.

[134]  M. Lenburg,et al.  Smad signaling is required to maintain epigenetic silencing during breast cancer progression. , 2010, Cancer research.

[135]  Konstantinos Mavridis,et al.  Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies , 2010, Biological chemistry.

[136]  J. Clements,et al.  Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. , 2010, Endocrine reviews.

[137]  M. Stack,et al.  Kallikrein-5 Promotes Cleavage of Desmoglein-1 and Loss of Cell-Cell Cohesion in Oral Squamous Cell Carcinoma* , 2010, The Journal of Biological Chemistry.

[138]  V. Magdolen,et al.  Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells. , 2010, The American journal of pathology.

[139]  A. Longatto-Filho,et al.  Analysis of human kallikrein 7 expression as a potential biomarker in cervical neoplasia , 2010, International journal of cancer.

[140]  P. Kantoff,et al.  Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  G. Yousef,et al.  Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs , 2010, Biological chemistry.

[142]  Long-Bang Chen,et al.  Frequent transcriptional inactivation of Kallikrein 10 gene by CpG island hypermethylation in non‐small cell lung cancer , 2010, Cancer science.

[143]  A. Scorilas,et al.  Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas. , 2010, Clinical biochemistry.

[144]  G. Yousef,et al.  Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer , 2010, British Journal of Cancer.

[145]  E. Diamandis,et al.  The physiology and pathobiology of human kallikrein-related peptidase 6 (KLK6) , 2012, Clinical chemistry and laboratory medicine.

[146]  Ankit Malhotra,et al.  miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. , 2011, Cancer research.

[147]  M. Srougi,et al.  MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. , 2011, The Journal of urology.

[148]  Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (KLK14) in malignant and benign breast tissues. , 2010, Thrombosis and haemostasis.

[149]  Yingye Zheng,et al.  Genomic instability and copy‐number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas , 2011, Molecular oncology.

[150]  J. Clements,et al.  Correlation of the expression of human kallikrein‐related peptidases 4 and 7 with the prognosis in oral squamous cell carcinoma , 2011, Head & neck.

[151]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[152]  A. Scorilas,et al.  Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions , 2011, Clinical Proteomics.

[153]  A. Scorilas,et al.  Expression analysis and clinical evaluation of kallikrein-related peptidase 10 (KLK10) in colorectal cancer , 2011, Tumor Biology.

[154]  M. Sallam,et al.  Diagnostic Value of Serum Kallikrein-Related Peptidases 6 and 10 Versus CA125 in Ovarian Cancer , 2011, International Journal of Gynecologic Cancer.

[155]  A. Scorilas,et al.  Kallikrein‐related peptidase 4 gene (KLK4) in prostate tumors: Quantitative expression analysis and evaluation of its clinical significance , 2011, The Prostate.

[156]  Y. Liu,et al.  MiR-382 targeting of kallikrein 5 contributes to renal inner medullary interstitial fibrosis. , 2012, Physiological genomics.

[157]  A. Scorilas,et al.  Diagnostic and prognostic significance of human kallikrein 11 (KLK11) mRNA expression levels in patients with laryngeal cancer. , 2012, Clinical biochemistry.

[158]  A. Scorilas,et al.  Kallikrein‐related peptidases (KLKs) as novel potential biomarkers in gastric cancer: An open yet challenging road lies ahead , 2012, Journal of surgical oncology.

[159]  A. Scorilas,et al.  Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance , 2012, Biological chemistry.

[160]  Georgia Sotiropoulou,et al.  One round of SELEX for the generation of DNA aptamers directed against KLK6 , 2012, Biological chemistry.

[161]  A. Scorilas,et al.  Highlight: the 4th International Symposium on Kallikreins and Kallikrein-related peptidases. , 2012, Biological chemistry.

[162]  E. Diamandis,et al.  Reference intervals and biological variation for kallikrein 6: influence of age and renal failure , 2012, Clinical chemistry and laboratory medicine.